Third and Fourth Generation Cephalosporins

Broad Spectrum with CSF Penetration

Third- and fourth-generation cephalosporins are characterized by extraordinary bactericidal potency against Gram-negative enteric pathogens, excellent penetration across the inflamed blood-brain barrier, and variable resistance to common beta-lactamases.

Mechanism

💊 Generic and Commercial Names

Tercera Gen: Ceftriaxona (Rocephin), Ceftacidima (Fortam), Cefotaxima (Claforan). Cuarta Gen: Cefepima (Maxipime).

🔬 Pharmacological Group

Beta-lactámicos. Cefalosporinas de amplio espectro sistémico con alta penetración al sistema nervioso central.

Mechanism of Action

Modulan covalentemente las PBPs esenciales del espacio periplásmico:

Estabilidad Química frente a Betalactamasas de Tercera Generación: La adición de un grupo aminotiazolil y un residuo metoximino en la posición de cadena lateral confiere a la ceftriaxona y cefotaxima una excelente estabilidad frente a la hidrólisis por penicilinasas de Gram-negativos y un aumento en la afinidad de unión por la PBP2 y PBP3 bacteriana.
Actividad Anti-Pseudomonas de Ceftacidima: Su cadena lateral incluye un grupo carboxipropiloxi que orienta específicamente su afinidad de unión hacia la PBP3 de Pseudomonas aeruginosa, facilitando su lisis osmótica, pero a expensas de perder casi toda la actividad contra cocos Gram-positivos.
Cefalosporinas de Cuarta Generación (Cefepima): Estructura de ion dipolar (zwitterion) que le permite atravesar de forma extraordinariamente rápida la membrana externa de Gram-negativos a través de las porinas. Su carga neta neutra disminuye significativamente su afinidad de unión y vulnerabilidad a la hidrólisis por betalactamasas de Clase C (AmpC) y betalactamasas cromosómicas inducibles.

Pharmacokinetics

Key Pharmacokinetics

Parameter	Ceftriaxone	Cefepime
Routes of Administration	Exclusively IV or IM. Not available orally.	Exclusively IV or IM.
Dural distribution	Excellent tissue penetration. It reaches concentrations in inflamed CSF of 10-15% of serum levels.	Excellent extracellular distribution, optimal penetration into inflamed CSF for the management of nosocomial meningitis.
Protein Binding	Very high (~85-95%) and saturable dose-dependent. Displaces bilirubin in neonates.	Low (~10-20%).
Metabolism	It does not undergo classical hepatic metabolism, but is partially degraded by the intestinal microflora after biliary excretion.	Minimal hepatic metabolism (<10%).
Excretion and Half-Life	Single double elimination: ~60% through the unaltered renal route and ~40% through the bile route to feces. Extraordinarily long half-life: 6.0 to 9.0 hours, allowing administration every 12-24 hours.	Pure glomerular renal excretion in 85% unchanged. Half-life of 2.0 to 2.3 hours.

Antimicrobial Spectrum

Ceftriaxone / Cefotaxime: Very high activity against Streptococcus pneumoniae (including strains with intermediate resistance to penicillin), N. meningitidis, N. gonorrhoeaeand common enterobacteria. They lack useful activity againstP. aeruginosa, MRSA, VRE or strict anaerobes.
Ceftacidime: Directed against Pseudomonas aeruginosa and enterobacteria. No coverage against Gram-positives.
Cefepime: Very broad spectrum. It combines the excellent Gram-positive activity of the first generation (robust coverage of MSSA and streptococci) with the Gram-negative coverage of the third generation, actively including Pseudomonas aeruginosa and strains producing derepressed AmpC.

Indicators and dose

Dosage and Adjustment

Ceftriaxone: 1 to 2 g IV every 12 or 24 hours (in severe pneumococcal meningitis it is dosed strictly at 2 g every 12 hours). It does not require dose adjustment in pure renal failure due to its double compensatory biliary clearance.
Cefepime: 1 to 2 g IV every 8 to 12 hours.
Adjustment of Cefepime in Renal Failure:
- Cl_cr 30-50 mL/min: Administer 1 to 2 g every 24 hours.
- Cl_cr 11-29 mL/min: Administer 500 mg at 1 g every 24 hours.
- Cl_cr < 10 mL/min: Administer 250 to 500 mg every 24 hours (or reduce according to close monitoring of neurotoxicity).

Security

Contraindications and ADRs

Contraindications: Allergy to cephalosporins. Ceftriaxone is absolutely contraindicated in premature hyperbilirubinemic neonates because it competitively displaces bilirubin from serum albumin, increasing the risk of storage encephalopathy (kernicterus).
Adverse Effects (ADR):
- Cholestasis and Biliary Sludge: Precipitation of ceftriaxone calcium crystals in the gallbladder (pseudolithiasis cholecystitis), reversible after stopping treatment.
- Cefepime encephalopathy (Dose-dependent): Drowsiness, stupor, myoclonus and non-convulsive status epilepticus. Favored by the systemic accumulation of cefepime in patients with advanced renal failure who did not undergo dose adjustment.

Risk of Precipitation of Ceftriaxone with Calcium Solutions

Simultaneous administration of Ceftriaxone with intravenous solutions containing calcium (such as Lactated Ringer's solution or total parenteral nutrition) may induce rapid formation of insoluble ceftriaxone-calcium precipitates in the dural bloodstream and target organs. This has caused pulmonary microembolism and fatal acute kidney failure, especially in neonates. The co-administration of ceftriaxone and calcium solutions through the same infusion route simultaneously is prohibited.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousFirst and Second Generation Cephalosporins NextFifth Generation Cephalosporins and Siderophores

System: Antimicrobial and Infectious
Cluster: Broad Spectrum with CSF Penetration

Download Epistemis